2018
DOI: 10.1002/sctm.18-0008
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: Stroke is a major cause of death and long‐term disability, affecting one in six people worldwide. The only currently available approved pharmacological treatment for ischemic stroke is tissue plasminogen activator; however, relatively few patients are eligible for this therapy. We hypothesized that intravenous (IV) infusion of banked unrelated allogeneic umbilical cord blood (UCB) would improve functional outcomes in patients with ischemic stroke. To investigate this, we conducted a phase I open‐label trial to… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
59
0
4

Year Published

2018
2018
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 83 publications
(63 citation statements)
references
References 65 publications
0
59
0
4
Order By: Relevance
“…In turn, altered cell interactions lead to an increased risk of BBB breakdown and may have significant adverse implications for injury-induced angiogenesis and repair [19]. Administration of UCBC in adult stroke induces changes in the neurovasculature, resulting in reduced brain neuropathology and improved neurological outcome [20,21]. It is unknown whether UCBC therapy mediates similar effects on the neurovascular unit in the neonatal brain.…”
Section: Introductionmentioning
confidence: 99%
“…In turn, altered cell interactions lead to an increased risk of BBB breakdown and may have significant adverse implications for injury-induced angiogenesis and repair [19]. Administration of UCBC in adult stroke induces changes in the neurovasculature, resulting in reduced brain neuropathology and improved neurological outcome [20,21]. It is unknown whether UCBC therapy mediates similar effects on the neurovascular unit in the neonatal brain.…”
Section: Introductionmentioning
confidence: 99%
“…When compared with bone marrow‐derived cells, UCB cells display improved immunotolerance and availability for infusion and may bolster recovery by downregulating inflammation and promoting neuroprotection and plasticity. Encouragingly, Laskowitz et al report that patients tolerated UCB therapy, did not suffer from any serious adverse events noted, and all participants exhibited improvements in functional outcome by 3 months postinfusion . The authors hope that these results, reported in STEM CELLS Translational Medicine , will support a randomized, placebo‐controlled phase II study.…”
Section: Featured Articlesmentioning
confidence: 83%
“…Discussion with local medicine agencies is required. There are many attempts to produce medicinal products derived from cryopreserved CB, including: allogeneic NK cells; T regs for tolerance treatments; antigen‐specific T cell lines; CB‐derived universal CAR‐T cells; off‐the‐shelf, expanded, CB‐derived CD34+ cells; and MNCs to treat condition like autism, cerebral palsy, or stroke . In our institution, we have started two approaches for developing cell banks: first, development of Good Manufacturing Practice (GMP)‐grade induced pluripotent stem cells (IPSCs) from confirmed homozygous donations.…”
Section: Other Uses Of the Cord Blood Inventoriesmentioning
confidence: 99%